Pradyumna Phatak

Summary

Publications

  1. doi request reprint Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes
    Farhan Imran
    Department of Medicine, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY 14621, USA
    Expert Rev Pharmacoecon Outcomes Res 9:297-304. 2009
  2. pmc A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
    Pradyumna Phatak
    Rochester General Hospital, Rochester, NY, USA
    Hepatology 52:1671-779. 2010

Detail Information

Publications2

  1. doi request reprint Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes
    Farhan Imran
    Department of Medicine, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY 14621, USA
    Expert Rev Pharmacoecon Outcomes Res 9:297-304. 2009
    ..Deferasirox may also have potential as an important supplement and even an alternative to phlebotomies in nontransfusional, genetic iron overload disorders, such as hereditary hemochromatosis...
  2. pmc A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
    Pradyumna Phatak
    Rochester General Hospital, Rochester, NY, USA
    Hepatology 52:1671-779. 2010
    ..After receiving deferasirox for 48 weeks, median serum ferritin levels decreased by 63.5%, 74.8%, and 74.1% in the 5, 10, and 15 mg/kg/day cohorts, respectively. In all cohorts, median serum ferritin decreased to < 250 ng/mL...